Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 7, 2005; 11(21): 3182-3188
Published online Jun 7, 2005. doi: 10.3748/wjg.v11.i21.3182
Published online Jun 7, 2005. doi: 10.3748/wjg.v11.i21.3182
Table 3 Correlation of CDX2 expression with clinico-pathological parameters and classifications in intestinal carcinomas according to Laurén.
| Parameter | n | CDX2 positive cases (%) |
| Age (yr) | ||
| ≤60 yr | 26 | 10 (38.5) |
| ＞60 yr | 44 | 30 (68.2) |
| P | 0.02 | |
| Gender | ||
| Female | 29 | 21 (72.4) |
| Male | 41 | 19 (46.3) |
| P | 0.03 | |
| pTNM stages | ||
| I | 21 | 13 (61.9) |
| II | 23 | 18 (78.3) |
| III | 17 | 4 (23.5) |
| IV | 9 | 5 (55.6) |
| P | 0.01 | |
| pN stages | ||
| pN0 | 22 | 14 (63.6) |
| pN1 | 26 | 18 (69.2) |
| pN2 | 20 | 6 (30) |
| pN3 | 2 | 2 (100) |
| P | 0.02 |
- Citation: Roessler K, Mönig SP, Schneider PM, Hanisch FG, Landsberg S, Thiele J, Hölscher AH, Dienes HP, Baldus SE. Co-expression of CDX2 and MUC2 in gastric carcinomas: Correlations with clinico-pathological parameters and prognosis. World J Gastroenterol 2005; 11(21): 3182-3188
- URL: https://www.wjgnet.com/1007-9327/full/v11/i21/3182.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i21.3182